放射性核素标记小分子多肽治疗肿瘤的研究进展

周玉凤

Receptor targeting therapy with radiolabeled peptides has become very important in oncology in the past few years. The most frequently used peptides in the clinic are analogs of somatostatin. Radiolabeled analogs of alpha-melanocyte-stimulating hormone, neurotensin, vasoactive intestinal peptide, bombesin, substance P, neuropeptide Y, gastrin and cholecystokinin are also being developed and evaluated in vitro and in vivo. This review focuses on the state of the art of the pre-clinical and clinical studies on ⁹⁰Y and ¹⁷⁷Lu radiolabeled somatostatin analogs for receptor-mediated radionuclide targeting therapy. Early clinical data of radiolabeled cholecystokinin and neuropeptide Y for internal radiopeptide therapy are also reviewed.

The recent development of receptor targeting therapy for tumors with radiopeptides

Department of Nuclear Medicine, Nantong Tumor Hospital, Nantong 226361, China

Received Date: 2004-08-19

Abstract: Receptor targeting therapy with radiolabeled peptides has become very important in oncology in the past few years. The most frequently used peptides in the clinic are analogs of somatostatin. Radiolabeled analogs of alpha-melanocyte-stimulating hormone, neurotensin, vasoactive intestinal peptide, bombesin, substance P, neuropeptide Y, gastrin and cholecystokinin are also being developed and evaluated in vitro and in vivo. This review focuses on the state of the art of the pre-clinical and clinical studies on ⁹⁰Y and ¹⁷⁷Lu radiolabeled somatostatin analogs for receptor-mediated radionuclide targeting therapy. Early clinical data of radiolabeled cholecystokinin and neuropeptide Y for internal radiopeptide therapy are also reviewed.

HTML

Reference (19)

[1]	Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases[J]. Apple Radiat Isot, 2002, 57(5):749-763.
[2]	Anthony LB, Woltering EA, Espenan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies[J]. Semin Nucl Med, 2002, 32(2):123-132.
[3]	Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with[In-DTPA] octreotide:the Rotterdam experience[J]. Semin Nucl Med, 2002, 32(2):110-122.
[4]	Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular for in vivo multireceptor tomour targeting[J]. Eur J Ncul Med Mol Imaging, 2002, 29(7):855-862.
[5]	Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of the somatostatin receptor subtypes2,3 and 5 forLabelling with various radiometals[J]. Eur J Nucl Med Mol Imaging, 2003, 30(10):1338-1347.
[6]	Kwekkeboom DJ, Kooij PP, Bakker WH, et al. Comparison of ¹¹¹InDOTA-Thy3-octreotide and ¹¹¹In-DTPA-octreotide in the same patients:biodistribution, kinetics organ and tumor uptak[J]. J Nucl Med, 1999, 40(5):762-767.
[7]	Chinol M, Bodei L, Cremonesi M, et al. Receptor-mediated radiotherapy with ⁹⁰Y-DOTA-dphe-Thy-octreotide:the experience of the European Institute of Oncology Group[J]. Semin Nucl Med, 2002, 32(2):141-147.
[8]	Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4GBq ⁹⁰Y-DOTATOC[J]. J Nucl Med, 2002, 43(5):610-616.
[9]	Waldherr C, Schumacher T, Maecke HR, et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90-yttrium-DOTATOC in neuroendocrine tumors?[J].Eur J Nucl Med, 2002, 29(Suppl):S100.
[10]	De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors:preclinical and clinical findings[J].Semin Nucl Med, 2002, 32(2):133-140.
[11]	Jonard P, Jamar F, Walrand S, et al. Tumor dosimetry based on PET86Y-DOTA-Tyr3-octreotide(SMT487)and CT-scan predicts tumor response to ⁹⁰Y-SMT487(OctreoTher)[J]. J Nucl Med, 2000, 41(Suppl):111P.
[12]	Schumacher T, Hofer S, Eichhorn k, et al. Local injection of the ⁹⁰Ylabelled peptidc vector DOTATOC to control gliomas of WHO grades Ⅱ and Ⅲ:an extended pilot study[J]. Eur J Nucl Med Mol Imaging,2002, 29(4):486-493.
[13]	Virgolini I, Britton K, Buscombe J, et al. In-and Y-DOTA-lanreotide:results and implications of the MAURITIUS trial[J]. Semin Nucl Med,2002, 32(2):148-155.
[14]	Kwekkeboom DJ, Bakker WH, Kooij PPM, et al.[¹⁷⁷Lu-DOTAO,Thy3] octreotate:comparison with[¹¹¹In-DOTA0] octreotide in patiens[J]. EurJ Nucl Med, 2001, 28(9):1319-1325.
[15]	Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patient with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue[¹⁷⁷Lu-DOTA (0), Thy3] octreotate[J].EurJ Nucl Med Mol Imaging, 2003, 30(3):417-422.
[16]	Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate:relation to neoplastic transformation[J]. Cancer Res,1999, 59(5):1152-1159.
[17]	Gugger M, Reubi JC. Gastrin-releasing peptide receptors in nonneoplastic and neoplastic human breast[J]. Am J Pathol, 1999, 155(6):2067-2076.
[18]	De Jong M, Breeman WA, Bernard BF, et al. Tumor Response After[(90)Y-DOTA(0), Thy(3)] octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size[J]. Eur J Nucl Med, 2001,42(12):1841-1846.
[19]	De Jong M, Beraard BF, Breeman WAP, et al. Combination of ⁹⁰Yand ¹⁷⁷Lu-labelled somatostatin analogs is superior for radionuclide therapy compared to ⁹⁰Y-or ¹⁷⁷Lu-labelled analogs only[J]. J Nucl Med,2002, 43(Suppl):123P-124P.

The recent development of receptor targeting therapy for tumors with radiopeptides

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views

The recent development of receptor targeting therapy for tumors with radiopeptides

HTML

Catalog